Stempoint Capital’s Neurogene NGNE Stock Holding History

Stempoint Capital’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-73,299	Closed	-$3.08M	–	70
2024 Q3	$3.08M	Sell	73,299 -5,302	-7%	-$206K	0.92%	30
2024 Q2	$2.86M	Buy	+78,601	New	+$2.77M	0.84%	36

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stempoint Capital's NGNE Position: Q4 2024 in Review

Stempoint Capital sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 73,299 shares — an estimated $3.08M sold.

Stempoint Capital first reported a position in NGNE in Q2 2024 and held it in 2 quarters. The position peaked at $3.08M in Q3 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

Stempoint Capital reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
Stempoint Capital sold 73,299 Neurogene shares in Q4 2024, an estimated $3.08M.
Stempoint Capital first reported a position in Neurogene in Q2 2024 and held it in 2 quarters.
Stempoint Capital's Neurogene position peaked at $3.08M in Q3 2024.
88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.